- Conditions
- Leukemia
- Interventions
- cyclophosphamide, topotecan hydrochloride
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 5,289
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged
- Interventions
- Revumenib, Blinatumomab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
- Interventions
- Ibrutinib, Idelalisib, Laboratory Biomarker Analysis, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Leukemia
- Interventions
- filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- clofarabine (IV formulation), placebo, cytarabine
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 41
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
- Conditions
- Leukemia
- Interventions
- filgrastim, rituximab, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 2
- States / cities
- Berkeley, California • San Francisco, California
- Conditions
- Fatigue, Leukemia, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- therapeutic touch
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- tipifarnib, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Cyclophosphamide, Dasatinib, Doxorubicin, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- obinutuzumab, rituximab, chlorambucil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 5
- States / cities
- San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, modified T cells
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia, Lymphoma
- Interventions
- aldesleukin, allogeneic natural killer cells, rituximab, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hodgkin's Disease, Multiple Myeloma, Non Hodgkin's Lymphoma
- Interventions
- Th2 cells in allo HSCTT, Th2 Cells
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • North Haven, Connecticut • Baltimore, Maryland + 6 more
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 15 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2011
- U.S. locations
- 86
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia
- Interventions
- Oral Clofarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma
- Interventions
- nelarabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 7
- States / cities
- Duarte, California • Tampa, Florida • Bethesda, Maryland + 4 more
- Conditions
- Relapsed Adult Acute Myeloid Leukemia, Refractory Adult Acute Myeloid Leukemia
- Interventions
- Merestinib, LY2874455
- Drug
- Lead sponsor
- Jacqueline Garcia, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
- Interventions
- Fostamatinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematologic Malignancies
- Interventions
- Busulfan, Fludarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Treatment patterns among AML patients, AML-related healthcare resources
- Other
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 3 more